ArticleCureus2025
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes mellitus (T2DM) significantly increases the risk of atherosclerotic cardiovascular disease (ASCVD), and optimal lipid control is essential for reducing major adverse cardiovascular events (MACE). However, despite the widespread use of statins, many high-risk diabetic patients fail to reach target low-density lipoprotein cholesterol (LDL-C) levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as effective adjunctive agents for lipid lowering. This study was conducted to evaluate the effect of PCSK9 inhibitors on lipid profile and cardiovascular outcomes in high-risk diabetic patients. Methods A prospective, observational study was conducted at Kakatiya Medical College/Mahatma Gandhi Memorial (MGM) Hospital Warangal over 18 months. A total of 100 patients with T2DM (age, 40-75 years), having established ASCVD or multiple cardiovascular risk factors and LDL-C >100 mg/dL despite maximal statin therapy, were included. All participants received proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab 75 mg or evolocumab 140 mg subcutaneously every two weeks) in addition to standard care. Lipid profile parameters were assessed at baseline, three months, and 12 months. MACE (non-fatal myocardial infarction, stroke, or cardiovascular death) was recorded and compared with a matched historical control group (n = 100) on statin therapy alone. Results At the end of 12 months, the PCSK9 inhibitor group (n = 100) showed a significant reduction in mean LDL-C from 138.5 ± 17.6 mg/dL to 64.3 ± 12.9 mg/dL (p < 0.001). An increase in high-density lipoprotein cholesterol (HDL-C) was observed from 40.8 ± 5.3 mg/dL to 45.1 ± 5.6 mg/dL (p = 0.04), and triglycerides reduced from 178.7 ± 25.2 mg/dL to 149.5 ± 19.8 mg/dL (p < 0.01). MACE occurred in seven out of 100 patients (7%) in the PCSK9 group, compared to 16 out of 100 patients (16%) in the control group (HR: 0.41; 95% CI: 0.17-0.98; p = 0.044). Specifically, non-fatal myocardial infarction occurred in three (3%) vs. seven (7%), stroke in two (2%) vs. five (5%), and cardiovascular death in two (2%) vs. four (4%) in the PCSK9 and control groups, respectively. No serious adverse drug reactions were reported among the PCSK9 users. Conclusion PCSK9 inhibitors significantly improve lipid parameters and reduce cardiovascular event rates in high-risk diabetic patients who are inadequately controlled with statins alone. These findings support their role as an effective and safe adjunctive therapy for secondary cardiovascular prevention in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.